Guerci B, Drouin P, Grangé V, Bougnères P, Fontaine P, Kerlan V, Passa P, Thivolet Ch, Vialettes B, Charbonnel B
Service de Diabétologie, Maladies Métaboliques & Maladies de la Nutrition, Hôpital Jeanne d'Arc, Centre Hospitalo-Universitaire de Nancy, BP 303, Dommartin-lès-Toul, 54201 Toul Cedex, France.
Diabetes Metab. 2003 Dec;29(6):587-94. doi: 10.1016/s1262-3636(07)70073-3.
Self monitoring of blood glucose (SMBG) in type 2 diabetes is a topic of current interest (imbalance between increased health-care costs and improvement in compliance with treatment and diet). An open label randomized prospective study was designed to compare changes in metabolic control over 6 months in patients managed with usual recommendations alone (conventional assessment group) or combined with SMBG.
Patients not treated with insulin or previously self monitored, 40 to 75 years of age, with a diagnosis of type 2 diabetes > 1 year and standardized HbA(1c) level > =7.5 and< =11% were randomized to either a control group or SMBG group. They were followed up every 6 weeks over 24 weeks. Patients in the SMBG group were given the same device (Ascensia Esprit Discmeter, Bayer) and were required to perform at least 6 capillary assays a week (3 different days of the week, including weekend). Management of patients was standardized, including drugs, diet and physical activity. The primary efficacy criterion was change in HbA(1c) level in Intent To Treat (ITT) patients. Assays were performed at baseline, at 3 and 6 months using the calibrated DCA 2000(R) device (Bayer).
Two hundred sixty five general practitioners randomized 988 patients (ITT Population), but 689 patients were evaluable for the primary criterion. At the endpoint, HbA(1c) was lower in the SMBG group (8.1 +/- 1.6%) than in the conventional treatment group (8.4 +/- 1.4%, P=0.012). The change in HbA(1c) levels between baseline and endpoint was classified into two classes: improvement if a change > 0.5% occurred, stability or worsening in case of a change< =0.5%; 57.1% of patients in the SMBG group vs 46.8% in the control group had an improvement in HbA(1c) level (P=0.007) after 3 months. A steady state was reached during the last 3 months. A multivariate logistic regression analysis was performed and identified factors predictive of improvement in HbA(1c) levels: HbA(1c) at baseline: odd ratio (OR)=1.749 (P<0.001), SMBG group (reference value: SMBG group): OR=0.665 (P=0.015), duration of diabetes: OR=0.953 (P=0.001) and BMI: OR=0.962 (P=0.039).
This study is the first multicenter, controlled, prospective trial conducted on a large number of patients demonstrating that SMBG was statistically associated with a better quality of metabolic control than usual traditional recommendations alone in type 2 diabetes.
2型糖尿病患者的血糖自我监测(SMBG)是当前备受关注的话题(医疗保健成本增加与治疗和饮食依从性改善之间的失衡)。一项开放标签随机前瞻性研究旨在比较仅采用常规建议管理的患者(传统评估组)或结合血糖自我监测管理的患者在6个月内代谢控制的变化。
年龄在40至75岁、未接受胰岛素治疗或之前未进行自我监测、确诊2型糖尿病超过1年且标准化糖化血红蛋白(HbA1c)水平≥7.5%且≤11%的患者被随机分为对照组或血糖自我监测组。在24周内每6周对他们进行一次随访。血糖自我监测组的患者使用相同的设备(拜耳Ascensia Esprit Discmeter血糖仪),并要求每周至少进行6次毛细血管检测(一周中的3个不同日子,包括周末)。对患者的管理进行了标准化,包括药物、饮食和体育活动。主要疗效标准是意向性治疗(ITT)患者糖化血红蛋白(HbA1c)水平的变化。在基线、3个月和6个月时使用校准后的DCA 2000(R)设备(拜耳)进行检测。
265名全科医生将988名患者随机分组(ITT人群),但689名患者可用于主要标准评估。在终点时,血糖自我监测组的糖化血红蛋白(HbA1c)水平(8.1±1.6%)低于传统治疗组(8.4±1.4%,P = 0.012)。糖化血红蛋白(HbA1c)水平在基线和终点之间的变化分为两类:如果变化>0.5%则为改善,变化≤0.5%则为稳定或恶化;3个月后,血糖自我监测组57.1%的患者糖化血红蛋白(HbA1c)水平有所改善,而对照组为46.8%(P = 0.007)。在最后3个月达到了稳定状态。进行了多变量逻辑回归分析,并确定了预测糖化血红蛋白(HbA1c)水平改善的因素:基线糖化血红蛋白(HbA1c):比值比(OR)=1.749(P<0.001),血糖自我监测组(参考值:血糖自我监测组):OR = 0.665(P = 0.015),糖尿病病程:OR = 0.953(P = 0.001)和体重指数(BMI):OR = 0.962(P = 0.039)。
本研究是首次对大量患者进行的多中心、对照、前瞻性试验,表明在2型糖尿病中,与仅采用常规传统建议相比,血糖自我监测在统计学上与更好的代谢控制质量相关。